Rigel CFO exercises options for 4,600 shares
Rigel’s CFO exercised options into 4,600 common shares, with 928 shares withheld or delivered to cover exercise costs.
Rhea-AI Filing Summary
RIGEL PHARMACEUTICALS INC (RIGL) reports that EVP & Chief Financial Officer Dean L. Schorno exercised employee stock options on September 2, 2026, converting a total of 4,600 option rights into 4,600 shares of common stock at exercise prices of $12.70, $18.70 and $24.20 per share. On September 1, 2026, 928 shares of common stock were delivered or withheld to pay the option exercise price or related tax liability. The option figures include awards that vest monthly over multi‑year periods, and no Rule 10b5‑1 trading plan is reported for these transactions.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
4,600 shares exercised/converted
Exercise
9 txns
Insider
Schorno Dean L
Role
EVP & Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) F3 | 694 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F4 | 620 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F2, F5 | 2,000 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F6 | 1,286 | $0.00 | $0.00 |
| Exercise | Common Stock | 694 | $12.70 | $9K |
| Exercise | Common Stock | 620 | $18.70 | $12K |
| Exercise | Common Stock F2 | 2,000 | $24.20 | $48K |
| Exercise | Common Stock | 1,286 | $24.20 | $31K |
| Exercise Price or Tax Liability | Common Stock F1 | 928 | $47.50 | $44K |
Holdings After Transaction:
Employee Stock Option (right to buy) — 45,702 contracts (Direct);
Common Stock — 82,962 shares (Direct)
Footnotes (6)
- F1. Includes 500 shares acquired under the Issuer's stock purchase plan.
- F2. These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
- F3. The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the Issuer through each such period.
- F4. The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.
- F5. The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer through each such period.
- F6. The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2020, subject to the Reporting Person's continuous service to the Issuer through each such period.
Key Figures
Options Exercised: 4,600 shares
Shares Delivered or Withheld: 928 shares
Exercise Price: $12.70 per share
+4 more
7 metrics
Options Exercised
4,600 shares
Employee stock options converted into common stock on September 2, 2026
Shares Delivered or Withheld
928 shares
Common shares used on September 1, 2026 to pay exercise price or tax liability
Exercise Price
$12.70 per share
One employee stock option exercise into common stock on September 2, 2026
Exercise Price
$18.70 per share
One employee stock option exercise into common stock on September 2, 2026
Exercise Price
$24.20 per share
Two employee stock option exercises into common stock on September 2, 2026
Reverse Stock Split Ratio
1-for-10
One option grant adjusted for reverse stock split effective June 27, 2024
Option Expiration Date
January 23, 2034
Expiration of one employee stock option grant exercised in part on September 2, 2026
Key Terms
reverse stock split, vesting commencement date, exercise price, tax liability
4 terms
reverse stock split financial
"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
vesting commencement date financial
"The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
exercise price financial
"Payment of exercise price or tax liability by delivering or withholding securities"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
tax liability financial
"Payment of exercise price or tax liability by delivering or withholding securities"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is the insider involved in the RIGL Form 4 filing and what is their role?
The Form 4 concerns Dean L. Schorno, who serves as EVP & Chief Financial Officer of RIGEL PHARMACEUTICALS INC. The filing reports his stock option exercises and related share dispositions in the company’s common stock.
How many Rigel (RIGL) stock options did the CFO exercise in this Form 4?
Dean L. Schorno exercised employee stock options covering 4,600 shares of RIGEL PHARMACEUTICALS INC common stock on September 2, 2026. These options converted into an equal number of common shares at stated exercise prices.
What exercise prices applied to the Rigel (RIGL) options exercised by the CFO?
The options exercised by the CFO on September 2, 2026 converted into common stock at exercise prices of $12.70, $18.70 and $24.20 per share. These prices correspond to different employee stock option grants with various expiration dates.
Did the Rigel (RIGL) CFO’s Form 4 transactions occur under a Rule 10b5-1 trading plan?
No. The filing indicates that no Rule 10b5-1 trading plan is reported for these transactions, so the option exercises and related share disposition are not described as occurring under a pre-arranged trading plan.
How were the Rigel (RIGL) option grants structured in terms of vesting?
The filing notes that certain option grants to the CFO vest monthly over periods of three or four years from vesting commencement dates in 2020, 2022, 2023 and 2024, subject to his continuous service with Rigel Pharmaceuticals.
Were the Rigel (RIGL) option figures in this Form 4 affected by a reverse stock split?
Yes. A footnote states that the reported numbers for one option grant were adjusted to reflect a one-for-ten reverse stock split that became effective on June 27, 2024, affecting the share and price figures for that grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
